Stroke and vascular neurology · 2026
Endovascular treatment for MILD ischaemic stroke with acute anterior circulation large vessel occlusion: a multicentre, prospective, randomised, clinical trial (MILD-MT) protocol.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Meihua, Yi Tingyu, Xing Pengfei, Wu Yan-Min, Lin Ding-Lai, Lin Xiaohui, Huang Ming-Zhu, Ren Zeguang, Liu Jianmin, Yang Pengfei, Zheng Tuanyuan, Zhang Meng, Wang Hao, Chen Wenhuo
Аннотация
BACKGROUND: Acute ischaemic stroke (AIS) with a National Institutes of Health Stroke Scale (NIHSS) score <6 is termed as mild stroke. The benefit of endovascular therapy (EVT) for patients with mild stroke caused by large vessel occlusion (LVO) is uncertain.
AIM AND DESIGN: MILD-MT trial is a multicentre, prospective, randomised, open-label, blinded endpoint (PROBE) trial designed to evaluate whether EVT combined with best medical management (EVT+BMM) is superior to BMM alone in patients with mild stroke due to anterior circulation LVO. Eligible patients have confirmed intracranial carotid artery (ICA), middle cerebral artery (MCA M1/M2) segment with or without ipsilateral extracranial ICA occlusion, symptom onset within 24 hours, small core infarct (≤50 mL), and substantial perfusion mismatch (≥50 mL), a profile indicating high risk for early neurological deterioration.
SAMPLE SIZE: Aim to randomise 300 patients 1:1 to receive EVT+BMM (intervention) or BMM alone (control).
STUDY OUTCOMES: The primary efficacy outcome is the proportion of excellent functional outcomes (defined as modified Rankin Scale 0 or 1 score) at 90±7 days. The primary safety outcomes include symptomatic intracranial haemorrhage within 48 hours according to the Heidelberg criteria; END is defined as an increase in NIHSS score ≥4 or ≥2 in any individual item within 7 days after randomisation and all-cause mortality at 90±7 days.
DISCUSSION: The MILD-MT trial could result in substantial evidence regarding the efficacy and safety of EVT for mild patients with AIS-LVO and large salvageable volume within 24 hours from symptom onset.
TRIAL REGISTRATION NUMBER: (NCT06179017).
AIM AND DESIGN: MILD-MT trial is a multicentre, prospective, randomised, open-label, blinded endpoint (PROBE) trial designed to evaluate whether EVT combined with best medical management (EVT+BMM) is superior to BMM alone in patients with mild stroke due to anterior circulation LVO. Eligible patients have confirmed intracranial carotid artery (ICA), middle cerebral artery (MCA M1/M2) segment with or without ipsilateral extracranial ICA occlusion, symptom onset within 24 hours, small core infarct (≤50 mL), and substantial perfusion mismatch (≥50 mL), a profile indicating high risk for early neurological deterioration.
SAMPLE SIZE: Aim to randomise 300 patients 1:1 to receive EVT+BMM (intervention) or BMM alone (control).
STUDY OUTCOMES: The primary efficacy outcome is the proportion of excellent functional outcomes (defined as modified Rankin Scale 0 or 1 score) at 90±7 days. The primary safety outcomes include symptomatic intracranial haemorrhage within 48 hours according to the Heidelberg criteria; END is defined as an increase in NIHSS score ≥4 or ≥2 in any individual item within 7 days after randomisation and all-cause mortality at 90±7 days.
DISCUSSION: The MILD-MT trial could result in substantial evidence regarding the efficacy and safety of EVT for mild patients with AIS-LVO and large salvageable volume within 24 hours from symptom onset.
TRIAL REGISTRATION NUMBER: (NCT06179017).